A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Cancer remains a leading cause of global morbidity and mortality, and conventional therapeutic strategies are often limited by poor tumor selectivity, ...

An unusual tale of discovery led to the 2006 finding of a protein expressed on the surface membrane of many types of cancerous cell, but only found on the inside of healthy cells 1. Today, this ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...

Ratain is the Leon O. Jacobson professor of medicine and the director of the Center for Personalized Therapeutics at the University of Chicago, and chairman of the board of the Optimal Cancer Care ...